Eisai will request reconsideration of initial decision for lecanemab in Australia

STOCKHOLM, Oct. 16, 2024 /PRNewswire/ — BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) partner Eisai announced today that the Therapeutic Goods Administration (TGA) of Australia issued a public statement about the initial decision not to register the humanized anti-soluble aggregated…